EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

IGSF11-Mediated Immune Modulation: Unlocking a Novel Pathway in Emerging Cancer Immunotherapies

Sapna Srivastava iD, Apriliana E R Kartikasari iD, Srinivasa Reddy Telukutla iD, Magdalena Plebanski iD, Dibyendu Banerjee

Cancers · 13.08.2025 · 17 (16) · 2636

DOI: 10.3390/cancers17162636 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.08.2025. Verfasst von Sapna Srivastava und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Health and Biomedical Science, Royal Melbourne Institute of Technology (RMIT), Bundoora, VIC 3083, Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC, CSIR-Pan Cancer Grant, CDRI In-house Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobulin superfamily member 11 (IGSF11) has recently emerged as a critical immune checkpoint ligand that interacts with the V-domain immunoglobulin suppressor of T-cell activation (VISTA) receptor to inhibit T-cell activation and promote immune escape. Preclinical studies have demonstrated that targeting the IGSF11-VISTA axis effectively reverses immunosuppression by enhancing T-cell effector functions and increasing the secretion of prostimulatory cytokines such as IFN-γ. This immune modulation shifts the tumor microenvironment from an immune “cold” state, characterized by low immune infiltration and activity, to a more immunoreactive “hot” state that is more susceptible to immune-mediated destruction. Moreover, combining IGSF11 inhibition with established therapies such as anti-PD-1/PD-L1 improves treatment efficacy in various cancer models. In this review, we focus on the immunomodulatory functions of IGSF11, its role in combination immunotherapies, and preclinical evidence supporting its potential as a novel therapeutic target to overcome resistance and improve cancer immunotherapy outcomes.

Schlagwörter

Stichwörter der Autor:innen

IGSF11VISTAcancerimmune checkpoint inhibitors

Autor:innen und Institutionen

  • School of Health and Biomedical Science, Royal Melbourne Institute of Technology (RMIT), Bundoora, VIC 3083, Australia.
  • Department, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
  • Cancer Biology Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, India.

ORCID-Profile: Sapna Srivastava, Apriliana E R Kartikasari, Srinivasa Reddy Telukutla, Magdalena Plebanski

Förderung

  • NHMRC
  • CSIR-Pan Cancer Grant
  • CDRI In-house Projects
  • RMIT University through the AcSIR-RMIT joint PhD program
  • National Health and Medical Research Council (NHMRC)

Zitieren

APA

Srivastava, S., Kartikasari, A. E. R., Telukutla, S. R., Plebanski, M., & Banerjee, D. (2025). IGSF11-Mediated Immune Modulation: Unlocking a Novel Pathway in Emerging Cancer Immunotherapies. Cancers, 17(16), 2636. https://doi.org/10.3390/cancers17162636

Vancouver

Srivastava S, Kartikasari AER, Telukutla SR, Plebanski M, Banerjee D. IGSF11-Mediated Immune Modulation: Unlocking a Novel Pathway in Emerging Cancer Immunotherapies. Cancers. 2025;17(16):2636. doi:10.3390/cancers17162636

BibTeX
@article{Srivastava2025,
  author = {Srivastava, Sapna and Kartikasari, Apriliana E R and Telukutla, Srinivasa Reddy and Plebanski, Magdalena and Banerjee, Dibyendu},
  title = {IGSF11-Mediated Immune Modulation: Unlocking a Novel Pathway in Emerging Cancer Immunotherapies},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {16},
  pages = {2636},
  doi = {10.3390/cancers17162636}
}
Kostenlos starten →